BioSpace News Archive

Taysha to have an exclusive option on new payloads, constructs, and intellectual property arising from research conducted under the agreement Agreement leverages Taysha’s existing partnership with UT Southwestern Gene Therapy Program to develop new constructs incorporating novel mini-gene payloads

Affinivax Announces Award from CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPS™ Vaccine Candidate into Clinical Trials Novel MAPS™ vaccine is designed to induce both a B-cell and T-cell protective immune response to multiple, highly conserved staphylococcal protein antigens

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has entered into a material transfer agreement with Biodextris Inc. for the use of three intranasal mucosal adjuvants in the Company’s Terra CoV-2 vaccine against COVID-19. Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300 and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides

- Fibrogen veteran brings global R&D expertise to Management Team - - Merck KGaA Executive Sophie (Zhengjie) Sun named Senior Vice President, Corporate Development bringing partnership, strategy and commercialization expertise - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment o

-- University of Michigan BioInterfaces Institute spinout has developed a technology to treat a wide range of life-threatening inflammatory diseases, including Acute Respiratory Distress Syndrome (ARDS)--

UVision360, Inc., an innovative FemTech company, announces today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s submission to expand the LUMINELLE® DTx System portfolio to now include the LUMINELLE 360° Bx (Biopsy) Sheath. The LUMINELLE® DTx System, is a compact hysteroscopy and cystoscopy system

Sotera Health Company, a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced financial results for the fourth-quarter and full-year 2020.

Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that the company will participate in two upcoming investor conferences.

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET

Initiative seeks to create interventions to prevent kidney failure and improve access to kidney disease research, care for communities of color